SI1537204T1 - Granzim b kot povzročitelj apoptoze odvisen od peptida Hsp Hsp v tumorskih celicah - Google Patents

Granzim b kot povzročitelj apoptoze odvisen od peptida Hsp Hsp v tumorskih celicah

Info

Publication number
SI1537204T1
SI1537204T1 SI200331798T SI200331798T SI1537204T1 SI 1537204 T1 SI1537204 T1 SI 1537204T1 SI 200331798 T SI200331798 T SI 200331798T SI 200331798 T SI200331798 T SI 200331798T SI 1537204 T1 SI1537204 T1 SI 1537204T1
Authority
SI
Slovenia
Prior art keywords
hsp70
granzyme
tumor cells
apoptosis
cells
Prior art date
Application number
SI200331798T
Other languages
English (en)
Inventor
Gabriele Prof Dr Multhoff
Original Assignee
Gabriele Prof Dr Multhoff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gabriele Prof Dr Multhoff filed Critical Gabriele Prof Dr Multhoff
Publication of SI1537204T1 publication Critical patent/SI1537204T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/50—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464476—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6467—Granzymes, e.g. granzyme A (3.4.21.78); granzyme B (3.4.21.79)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/07—Heat shock proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
SI200331798T 2002-08-23 2003-08-22 Granzim b kot povzročitelj apoptoze odvisen od peptida Hsp Hsp v tumorskih celicah SI1537204T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02018284 2002-08-23
PCT/EP2003/009341 WO2004018002A2 (en) 2002-08-23 2003-08-22 Use of granzyme b as an hsp70/hsp70 peptide dependent inducer of apoptosis in tumor cells
EP03792414A EP1537204B1 (en) 2002-08-23 2003-08-22 Granzyme b as an hsp70/hsp70 peptide dependent inducer of apoptosis in tumor cells

Publications (1)

Publication Number Publication Date
SI1537204T1 true SI1537204T1 (sl) 2010-06-30

Family

ID=31896833

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200331798T SI1537204T1 (sl) 2002-08-23 2003-08-22 Granzim b kot povzročitelj apoptoze odvisen od peptida Hsp Hsp v tumorskih celicah

Country Status (13)

Country Link
US (1) US7722863B2 (sl)
EP (1) EP1537204B1 (sl)
JP (1) JP4699755B2 (sl)
AT (1) ATE457349T1 (sl)
AU (1) AU2003260452A1 (sl)
CA (1) CA2535952A1 (sl)
CY (1) CY1110005T1 (sl)
DE (1) DE60331228D1 (sl)
DK (1) DK1537204T3 (sl)
ES (1) ES2340270T3 (sl)
PT (1) PT1537204E (sl)
SI (1) SI1537204T1 (sl)
WO (1) WO2004018002A2 (sl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2079833A1 (en) * 2006-11-14 2009-07-22 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Compositions and methods for immunotherapy
KR101192724B1 (ko) 2010-02-04 2012-10-18 한국생명공학연구원 마이크로알엔에이의 발현을 조절하여 ｎｋ 세포를 활성화시키는 방법
PT2606125T (pt) 2010-08-20 2018-02-27 Immunovative Therapies Ltd Células que expressam características th1 e propriedades citolíticas
WO2018005926A1 (en) 2016-07-01 2018-01-04 The General Hospital Corporation Granzyme b directed imaging and therapy
WO2019043170A1 (en) 2017-08-31 2019-03-07 Multimmune Gmbh POLY THERAPY BASED ON HSP70
CN115477705B (zh) * 2021-06-16 2024-02-23 四川大学华西医院 一种基于颗粒酶b构建的嵌合抗原受体免疫细胞制备及其应用
CN115305238B (zh) * 2022-09-19 2023-11-17 杭州凤喆凰生物科技有限公司 一种提高自然杀伤细胞杀伤力的成分在自然杀伤细胞培养中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6130087A (en) * 1996-10-07 2000-10-10 Fordham University Methods for generating cytotoxic T cells in vitro
CA2298867A1 (en) * 1997-08-18 1999-02-25 Center For Blood Research, Inc. Methods for using granzymes and binding molecules thereof for treating diseases characterized by abnormal apoptosis
BR9909250A (pt) * 1998-02-27 2001-09-04 Boehringer Ingelheim Pharma Apoptose auto-regulada de células inflamatórias através de terapia genética
CA2325735C (en) * 1998-03-27 2013-06-04 Gabriele Multhoff Hsp70 protein for the treatment of tumours, cancer or infectious diseases through nk-cell activation
DE19813759C1 (de) * 1998-03-27 1999-07-15 Gsf Forschungszentrum Umwelt Verfahren zur Induktion einer durch NK-Zellen vermittelten Immunantwort
FR2792205B1 (fr) * 1999-04-19 2001-07-27 Inst Nat Sante Rech Med Composition pharmaceutique comprenant des cellules nkt activees par des pim, et son utilisation en therapie
AU2001262216A1 (en) * 2000-04-22 2001-11-07 Stefan Barth Apoptotic agents
US20040014652A1 (en) * 2000-06-01 2004-01-22 Andre Trouet Tumor activated prodrug compounds and methods of making and using the same
EP1286700A2 (en) * 2000-06-01 2003-03-05 Universite Catholique De Louvain Tumor activated prodrug compounds
ATE430161T1 (de) * 2000-09-13 2009-05-15 Multimmune Gmbh Peptid aus hsp70 welches nk zellaktivtät stimuliert und seine verwendung
DK1414471T3 (da) * 2001-07-17 2012-07-16 Res Dev Foundation Terapeutiske midler omfattende pro-apoptotiske proteiner

Also Published As

Publication number Publication date
AU2003260452A8 (en) 2004-03-11
DK1537204T3 (da) 2010-06-07
CY1110005T1 (el) 2015-01-14
PT1537204E (pt) 2010-05-05
EP1537204B1 (en) 2010-02-10
US7722863B2 (en) 2010-05-25
JP2006507810A (ja) 2006-03-09
CA2535952A1 (en) 2004-03-04
WO2004018002A3 (en) 2004-06-17
AU2003260452A1 (en) 2004-03-11
DE60331228D1 (de) 2010-03-25
US20060111285A1 (en) 2006-05-25
ATE457349T1 (de) 2010-02-15
EP1537204A2 (en) 2005-06-08
JP4699755B2 (ja) 2011-06-15
ES2340270T3 (es) 2010-06-01
WO2004018002A2 (en) 2004-03-04

Similar Documents

Publication Publication Date Title
SA522432139B1 (ar) بروتينات ربط متعددة الخصوصية لمعالجة السرطان
MY140539A (en) 1-amino 1h-imidazoquinolines
DE69929232D1 (de) Virusähnliche partikel zur induktion von autoantikörpern
PT1309589E (pt) Compostos de ureia e metodos de utilizacao
BRPI0418251C1 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
BRPI0416936A (pt) sistemas de anel de imidazo substituìdos e métodos
WO2004024097A8 (en) Compositions and methods for the treatment of immune related diseases
WO2004043361A3 (en) Compositions and methods for the treatment of natural killer cell related diseases
EA200600424A1 (ru) Применение полипептидов семейства купредоксинов при лечении рака
DE60011100D1 (de) Als cox-hemmer verwendbare sulfonylphenylpyrazol-verbindungen
NO20055209L (no) Peptabody for cancerbehandling
CY1110005T1 (el) Γρανζυμο β ως ενας επαγωγεας αποπτωσης κυτταρων ογκων εξαρτωμενος απο ενα hsp70/hsp70 πεπτιδιο
GB2453491A (en) Immunogenic proteins of burkholderia pseudomallei and uses thereof
DE60319083D1 (de) Pharmazeutische verbindung und methoden zur behandlung von menschlichen karzinomen mittels arginin entzug
EA200500871A1 (ru) Пептиды, ингибирующие ангиогенез, миграцию клеток, инвазию клеток и пролиферацию клеток, композиции и их применение
BR0009170A (pt) ácidos nucléicos akt, polipeptìdeos e uso dos mesmos
GB0418388D0 (en) Cell therapy
EA200401586A1 (ru) Композиции для терапевтического использования, включающие витамин а, соль металла и инсулин либо гормон роста
DE602005024161D1 (de) Peptid mit antitumoraler wirkung
CY1109524T1 (el) Τροποποιημενη ανθρωπινη δισμουταση υπεροξειδιου μαγγανιου και οι χρησεις της
UA83989C2 (ru) Выделенный пептид, который стимулирует противоопухолевый иммунный ответ, фармацевтическая композиция на его основе и ее применение
WO2007082052A3 (en) Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases
DE60130775D1 (de) Stimulierung der neutrophilfunktion zur behandlung von entzündlichen darmerkrankungen
ATE544453T1 (de) Kombinationstherapien mit l-fmau zur behandlung von hepatitis-b-virus-infektionen
ATE315406T1 (de) Semi-allogene antitumor-vakzine mit hla-haplo- identischen antigen-präsentierenden zellen